CG Oncology (CGON) vs Kymera Therapeutics (KYMR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
CG Oncology (CGON) has outperformed Kymera Therapeutics (KYMR) over the past year, gaining 87.3% versus a gain of 74.6%. Kymera Therapeutics is the larger company by market cap ($9.84 billion vs $7.10 billion), about 1.4 times the size, while CG Oncology is growing revenue faster (+254.7% vs -16.7%). Kymera Therapeutics converts more of its revenue into profit, with a net margin of -794.0% versus -3985.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGON | KYMR |
|---|---|---|
| Share price | $79.47 | $115.31 |
| Market cap | $7.10B | $9.84B |
| 1-day change | -2.97% | -3.42% |
| YTD return | +91.40% | +48.19% |
| 1-year return | +87.25% | +74.61% |
| 5-year return | — | +114.37% |
| EPS (TTM) | $-2.76 | $-3.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.04M | $39.21M |
| Revenue growth (YoY) | +254.70% | -16.70% |
| Net income (latest FY) | $-161.00M | $-311.35M |
| Gross margin | — | 0.00% |
| Operating margin | -4722.13% | -891.07% |
| Net margin | -3985.02% | -794.04% |
| 52-week high | $93.95 | $142.92 |
| 52-week low | $37.01 | $63.69 |
| Distance from 52-week high | -15.41% | -19.32% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +38.03% | +25.94% |
| Average volume | 1.24M | 852.46K |
| Shares outstanding | 89.32M | 85.37M |
| Employees | 142 | 285 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CGON has outperformed KYMR by 12.6 percentage points over the past year.
- Kymera Therapeutics is more profitable, keeping -794.0 cents of every revenue dollar as net income versus -3985.0 cents for CG Oncology.
- CG Oncology grew revenue faster in its latest fiscal year (+254.70% vs -16.70%).
About CG Oncology
CGON stock →CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees
About Kymera Therapeutics
KYMR stock →Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 285 employees
CGON vs KYMR FAQ
Which is bigger, CG Oncology or Kymera Therapeutics?
Kymera Therapeutics (KYMR) is larger, with a market capitalization of $9.84B compared with $7.10B for CG Oncology (CGON).
Which stock has performed better over the past year, CGON or KYMR?
CGON returned +87.25% over the past 12 months, compared with +74.61% for KYMR (price return, excluding dividends). Past performance does not predict future results.
Are CG Oncology and Kymera Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.